Mirum Pharmaceuticals, Inc.
MIRM
Positions held
Your positionsMIRM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Mirum Pharmaceuticals operates in the biotechnology sector, which is known for its potential for high growth and innovation, especially in developing treatments for rare diseases.
- Revenue increased by 10% compared to the prior quarter, reaching $176 million.
- Gross margin improved to 82.8%, up from 82% in the previous quarter.
- The company has a negative profit margin of -1.39, indicating ongoing financial challenges.
- Operating margin remains negative at -14.81% for the latest quarter.
- The stock has a strong sell signal with a score of -16.00, reflecting bearish trends in market indicators.
Fundamentals
| Market cap | $5.28B | Enterprise value | $5.61B | Trailing P/E | — | Forward P/E | -234.66 |
| PEG | — | Price / book | -505.28 | Beta | 0.62 | Dividend yield | 0.00% |
| Revenue growth | 37.9% | Earnings growth | — | Gross margin | 81.7% | Operating margin | -14.8% |
| Profit margin | -139.2% | ROE | -7.0% | ROA | -6.8% | Debt / equity | — |
| Current ratio | 2.86 | Free cash flow | $76.62M | Analyst recommendation | strong_buy | Mean target | $145.79 |
| 52w high | $130.00 | 52w low | $63.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $176M | $160M | $149M | $133M | $128M | — |
| Op margin | -14.8% | -39.5% | -3.1% | 2.0% | -3.9% | — |
| Net income | -$67.2M | -$790M | -$5.7M | $2.9M | -$5.9M | — |
| Gross margin | 82.8% | 82.0% | 81.0% | 80.8% | 81.7% | — |
| Gross profit | $146M | $131M | $121M | $107M | $104M | — |
| Operating income | -$26.1M | -$63.2M | -$4.6M | $2.6M | -$5.0M | — |
- Revenue +10% vs prior quarter ($176M vs $160M).
- Gross margin 82.8% (was 82% prior quarter).
- Operating margin expanded to -14.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $521M | $337M | $186M | $77.1M | — |
| Op margin | -4.2% | -26.0% | -58.6% | -170.3% | — |
| Net income | -$23.4M | -$87.9M | -$163M | -$136M | — |
| Gross margin | 80.8% | 75.8% | 74.8% | 83.9% | — |
| Gross profit | $421M | $255M | $139M | $64.7M | — |
| Operating income | -$22.1M | -$87.6M | -$109M | -$131M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Raises Price Target on Mirum Pharmaceuticals to $155 From $135, Keeps Outperform Rating
2026-10-02 · Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
2026-09-30 · PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
2026-09-29 · Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
2026-09-29 · Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data?
2026-09-28 · MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
2026-09-28 · Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
2026-09-28 · FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
2026-09-28 · Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA
Price (daily)
Full chart · RSI · MACD · patterns